1. Project profile

Modality: Masked TCE trispecific antibody

Target : FOLR1, PD-L1, CD3

Indications: Ovarian Cancer, NSCLC

Research phase: PCC

Cooperation demands: license out

2. Highlights

Ø Compared with the FOLR1×CD3 bispecific antibody, the FOLR1×PD-L1 × CD3 trispecific antibody fully covers the whole“target‑activate‑sustain” workflow for solid tumor treatment, delivering robust mechanistic support for superior anti‑tumor efficacy;

Ø The proprietary protease‑responsive masking technology platform has been clinically validated in human trials;

Ø Asset shows better in vivo antitumor activity than masked FOLR1/CD3 bsAb + anti-PD-L1 mAb combination;

3. Results and data

Ø Asset-mediated T-cell activation is strictly dependent on the expression of FOLR1 and PD-L1, as well as on tumor cells.

Ø Non-cleavable: No killing activity on PD-L1/FOLR1 positive cells→strictly protease-dependent (blocking >1,000×), safe without tumor proteases.

Ø Cleavable: Potent killing activity on PD-L1/FOLR1 positive cells, activity comparable to Umasked FOLR1/PD-L1/CD3 tsAb→tumor-secreted proteases are sufficient for full reactivation.

Ø Asset shows better in vivo antitumor activity than masked FOLR1/CD3 bsAb + anti-PD-L1 mAb combination